Palantir Technologies Inc. (PLTR)

Palantir's stock has pulled back into the middle of its 52-week range after a sharp selloff over the past month. The price of $168.82 sits 19.24% below where it was a month ago, but it remains 9.95% above its 200-day average. Analysts have just reaffirmed their stance after the November 2, 2026 earnings report, when the company beat the EPS estimate by 7.32% yet the shares fell 1.65% in the next session. For investors, the question is whether the company's strong growth and earnings beats can outweigh a valuation that already prices in a great deal.

Palantir reported adjusted EPS of $0.44 for the report dated November 2, 2026, against an analyst estimate of $0.41, a beat of 7.32%. Despite those figures, the share price fell 1.65% in the first session after the report. The company has beaten the EPS estimate in six of its last seven reports, but in three of those six cases the shares still closed lower in the first session. That pattern suggests investors are judging the stock on expectations for the next quarter rather than on the headline beat.

The trailing P/E of 119.15 is at a premium to peers, 239.5% above the sector median P/E of 35.1. The price-to-sales ratio of 55.94 is 636.1% above the sector median of 7.6. The trailing GAAP EPS is $1.42, so the stock's price is far above what the trailing reported earnings support. Investors are paying for the forecast growth: analysts expect fiscal 2026 EPS of $1.70, up 126.9%, and fiscal 2027 EPS of $2.54, up 49.0% more. The stock therefore depends on that growth arriving as forecast.

Of 33 analysts with a current rating, 22 rate the stock buy or strong buy, 9 hold it and 2 sell it. Three months earlier, 21 of 32 ratings were buy. On November 3, 2026, Citigroup, Truist Securities, DA Davidson and Rosenblatt all kept buy ratings, RBC Capital kept its Underperform rating, and on November 4, 2026, Barclays kept its Overweight rating. Insiders sold $1.3B of stock across 78 sales over the last 18 months and made no open-market purchases. Those sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than purchases would be.

The stock is 9.95% above its 200-day average of $153.54 but 8.84% below its 50-day average of $185.19, so the trend is mixed. The 14-day RSI of 39.2 sits in the bearish zone, and the MACD line is negative. Over one year it is down 12.80%.

The base case is that the stock keeps trading between its long-term average and its recent highs while the market tests whether earnings growth can keep pace with the price. Analysts expect fiscal 2026 EPS to rise 126.9% to $1.70 and fiscal 2027 EPS to rise a further 49.0% to $2.54, which is the main reason the median 12-month target of $235.00 sits 39.2% above the price. The bull case rests on further beats and on the stock reclaiming its 50-day average of $185.19, which would confirm that the recent weakness was a pause rather than a change in trend. The bear case is that growth slows faster than expected, or that the high valuation, with a trailing P/E of 119.15, leaves little room for disappointment. Among analysts, the lowest target of $80.00 shows how wide the range of views is. Any run toward the 52-week high of $212.94 would depend on the next earnings releases confirming the growth forecasts.

Support sits first at the 200-day simple moving average of $153.54, which the price has held above and which would be the first line to test on a sustained fall. Below that is the 52-week low of $106.37, a far more distant floor that marks the bottom of the past year's trading. Resistance is the 20-day exponential moving average of $180.95, the nearest level above the price and the first hurdle for any recovery. Next is the 50-day simple moving average at $185.19, which the stock has been trading below. The 52-week high of $212.94 is the furthest level above and the top of the past year's range.